Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
Compelling evidence suggest that vascular endothelial growth factor (VEGF) and its receptors, especially receptor 2 (VEGFR2, or kinase insert domain-containing receptor, KDR), play a critical role in angiogenesis under both physiological and pathological conditions, including cancer and angiogenic retinopathies such as age-related macular degeneration (AMD). To this end, inhibition of angiogenesis with antagonists to either VEGF or KDR has yielded significant therapeutic efficacy both in preclinical studies in animal models and in clinical trials in patients with cancer and AMD. We previously reported the identification of a high affinity, fully human anti-KDR antibody fragment, 1121B Fab, through a highly stringent affinity maturation process with a Fab originally isolated from a naïve human antibody phage display library. In this study, we demonstrate that 1121B Fab is able to strongly block KDR/VEGF interaction, resulting in potent inhibition of an array of biological activities of VEGF, including activation of the receptor and its signaling pathway, intracellular calcium mobilization, and migration and proliferation of endothelial cells. Taken together, our data lend strong support to the further development of 1121B Fab fragment as an anti-angiogenesis agent in both cancer and angiogenic retinopathies.
Miao
Hua-Quan
HQ
Departments of Antibody Technology, Protein Science, and Cell Engineering and Expression, ImClone Systems Incorporated, New York, NY 10014, USA. hua-quan.miao@imclone.com
Hu
Kun
K
Jimenez
Xenia
X
Navarro
Elizabeth
E
Zhang
Haifan
H
Lu
Dan
D
Ludwig
Dale L
DL
Balderes
Paul
P
Zhu
Zhenping
Z